CA2864838A1 - Activated immunostimulatory cell composition for therapy of infection - Google Patents

Activated immunostimulatory cell composition for therapy of infection Download PDF

Info

Publication number
CA2864838A1
CA2864838A1 CA2864838A CA2864838A CA2864838A1 CA 2864838 A1 CA2864838 A1 CA 2864838A1 CA 2864838 A CA2864838 A CA 2864838A CA 2864838 A CA2864838 A CA 2864838A CA 2864838 A1 CA2864838 A1 CA 2864838A1
Authority
CA
Canada
Prior art keywords
cells
aicc
leukocytes
composition
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2864838A
Other languages
English (en)
French (fr)
Inventor
Irene Ginis
Alan Smith
Marina Bubis
Mitchell Shirvan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrocure Ltd
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of CA2864838A1 publication Critical patent/CA2864838A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864838A 2012-03-15 2013-03-13 Activated immunostimulatory cell composition for therapy of infection Abandoned CA2864838A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611180P 2012-03-15 2012-03-15
US61/611,180 2012-03-15
PCT/IB2013/000935 WO2013136191A1 (en) 2012-03-15 2013-03-13 Activated immunostimulatory cell composition for therapy of infection

Publications (1)

Publication Number Publication Date
CA2864838A1 true CA2864838A1 (en) 2013-09-19

Family

ID=48483110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864838A Abandoned CA2864838A1 (en) 2012-03-15 2013-03-13 Activated immunostimulatory cell composition for therapy of infection

Country Status (8)

Country Link
US (1) US20150071892A1 (show.php)
EP (1) EP2825182A1 (show.php)
JP (1) JP2015509974A (show.php)
CA (1) CA2864838A1 (show.php)
IN (1) IN2014DN08407A (show.php)
MX (1) MX2014010893A (show.php)
RU (1) RU2014140795A (show.php)
WO (1) WO2013136191A1 (show.php)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013005610A2 (pt) 2010-09-09 2019-09-24 Macrocure Ltd sobrenadante condicionado de leucócito, alcs, método para o tratamento de uma ferida, método para a inibição do surgimento de infecção em uma ferida, método, sobrenadante e produto
EP3516045A1 (en) * 2016-09-23 2019-07-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
US20200345800A1 (en) * 2017-10-03 2020-11-05 Tokyo Metropolitan Institute Of Medical Science Medication for influenza

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US8012468B2 (en) 2004-06-11 2011-09-06 Catholic Universtiy Industry Academic Cooperation Foundation Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CN102438635B (zh) 2009-03-05 2014-09-17 马克罗柯尔有限公司 活化的白细胞组合物

Also Published As

Publication number Publication date
WO2013136191A1 (en) 2013-09-19
EP2825182A1 (en) 2015-01-21
JP2015509974A (ja) 2015-04-02
US20150071892A1 (en) 2015-03-12
MX2014010893A (es) 2015-06-23
RU2014140795A (ru) 2016-05-10
IN2014DN08407A (show.php) 2015-05-08

Similar Documents

Publication Publication Date Title
JP4610847B2 (ja) すぐ使用できる、抗原負荷また非負荷の凍結保存された成熟成樹状細胞の調製方法
Thurner et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
CA2647622C (en) Compositions for the preparation of mature dendritic cells
US12098387B2 (en) Methods for generating engineered human primary blood dendritic cell lines
JP2016190868A (ja) 同種異系細胞治療：ミラー効果
JP7397493B2 (ja) 治療用途のための樹状細胞のｉｎ ｖｉｔｒｏ分化および成熟のための方法
JP5016489B2 (ja) 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
Itoh et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells
Sili et al. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
US20150071892A1 (en) Activated Immunostimulatory Cell Composition for Therapy of Infection
WO2013134464A1 (en) Tissue constructs and uses thereof
JP6283347B2 (ja) 成熟樹状細胞集団の製造方法
US20150030635A1 (en) Activated Immunostimulatory Cell Composition and Uses Thereof
US20240076616A1 (en) Method for t-cell expansion and related medical applications
WO2020196297A1 (ja) 免疫細胞提供方法
JP2006505259A (ja) 疾患特異的細胞傷害性ｔリンパ球の集団を産生および利用する手段
Samuel Novel approaches for the isolation and expansion of cytomegalovirus-specific T cells for adoptive immunotherapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170314